Neuroblastomas Clinical Studies

Some of the many Cancer and Blood Disorders research opportunities available related to neuroblastomas are listed below. Select a study to review a brief description and requirements. Parents or guardians of children who might be eligible are encouraged to inquire about enrollment. Contact information is provided at the end of each study.

Please note that Pilot and Phase I studies are the most experimental and should be considered only after other treatments or trials have been attempted without success.

Thank you for exploring these opportunities and helping us to find cures and prevent childhood disease.

Clinical Studies

Researchers

Pediatric Tumors and Specimen Study

A Children’s Oncology Group Protocol for Collecting and Banking Pediatric Specimens Including Rare Pediatric Tumors

Read more

Solid Tumor Treatment with MLN4924, Temozolomide & Irinotecan

ADVL1615: Study of Pevonedistat (MLN4924), a NEDD8-Activating Enzyme Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Read more

Solid Tumor Treatment With nab-Rapamycin, Temozolomide & Irinotecan – Phase I

ADVL1514: Study of ABI-009 (nab-Rapamycin) in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors, as a Single Agent and in Combination with Temozolomide and Irinotecan

Read more

Solid Tumor Treatment with Palbociclib – Phase I

ADVL1921: Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (IBRANCE®) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors

Read more

Solid Tumor Treatment with Selinexor – Phase I

ADVL1414: Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors Including CNS Tumors

Read more